A Lack of Serotonin 1B Autoreceptors Results in Decreased Anxiety and Depression-Related Behaviors

Katherine M Nautiyal1,2, Laurent Tritschler3, Susanne E Ahmari4, Denis J David3, Alain M Gardier3 and René Hen1,1,2,5

1Department of Psychiatry, Columbia University, New York, NY, USA; 2Division of Integrative Neuroscience, The New York State Psychiatric Institute, New York, NY, USA; 3Université Paris-Saclay, University Paris-Sud, Faculté de Pharmacie, CESP, INSERM UMRS 1178, Chatenay-Malabry, France; 4Department of Psychiatry, Translational Neuroscience Program, Center for Neuroscience Program, Center for the Neural Basis of Cognition, University of Pittsburgh, Pittsburgh, PA, USA; 5Department of Neurosciences, Columbia University, New York, NY, USA

The effects of serotonin (5-HT) on anxiety and depression are mediated by a number of 5-HT receptors, including autoreceptors that act to inhibit 5-HT release. While the majority of anxiety and depression-related research has focused on the 5-HT1A receptor, the 5-HT1B receptor has a lesser known role in modulating emotional behavior. 5-HT1B receptors are inhibitory GPCRs located on the presynaptic terminal of both serotonin and non-serotonin neurons, where they act to inhibit neurotransmitter release. The autoreceptor population located on the axon terminals of 5-HT neurons is a difficult population to study due to their diffuse localization throughout the brain that overlaps with 5-HT1B heteroreceptors (receptors located on non-serotonergic neurons). In order to study the contribution of 5-HT1B autoreceptors to anxiety and depression-related behaviors, we developed a genetic mouse model that allows for selective ablation of 5-HT1B autoreceptors. Mice lacking 5-HT1B autoreceptors displayed the expected increases in extracellular serotonin levels in the ventral hippocampus following administration of a selective serotonin reuptake inhibitor. In behavioral studies, they displayed decreased anxiety-like behavior in the open field and antidepressant-like effects in the forced swim and sucrose preference tests. These results suggest that strategies aimed at blocking 5-HT1B autoreceptors may be useful for the treatment of anxiety and depression.

Neuropsychopharmacology advance online publication, 20 July 2016; doi:10.1038/npp.2016.109

INTRODUCTION

Dysregulation of serotonin signaling is present in a number of mood-related psychiatric disorders, including major depressive disorder (Lucki, 1998; Ressler and Nemeroff, 2000). Serotonin (5-HT) autoreceptors play a major role in regulating serotonergic tone and modulating the response to antidepressant pharmacotherapies (Richardson-Jones et al, 2010; Stamford et al, 2000). While the majority of research has focused on serotonin 1A (5-HT1A) autoreceptors, evidence also points to serotonin 1B (5-HT1B) autoreceptors as a major regulator of serotonin transmission and emotionality (Donaldson et al, 2014; McDevitt and Neumaier, 2011; Richardson-Jones et al, 2010). In rodent models, activation of 5-HT1B receptors decreases serotonin levels through effects on release, synthesis, and reuptake (Hagan et al, 2012; Hjorth et al, 1995; Trillat et al, 1997). Additionally, 5-HT1B knockout mice have increased levels of 5-HT, compared with wild-type mice, following administration of a selective serotonin reuptake inhibitor (SSRI) (Knobelmann et al, 2001; Malagie et al, 2001). Behaviorally, an absence of all 5-HT1BRs in mice results in decreased depressive behaviors (Bechtholt et al, 2008; Jones and Lucki, 2005; Mayorga et al, 2001). However, these studies were not able to directly distinguish the contribution of autoreceptors from the rest of 5-HT1BRs.

5-HT1B Rs are inhibitory Gi/Go coupled GPCRs expressed on axon terminals, which act to inhibit terminal neurotransmitter release (Boschert et al, 1994; Ghavami et al, 1999; Mizutani et al, 2006). In addition to the population of 5-HT1B autoreceptors located on serotonin neurons, 5-HT1B heteroreceptors are located on the presynaptic terminals of non-serotonergic neurons, including GABA, ACh, and glutamate neurons (Sari, 2004). These distinct populations can act in different or sometimes opposing roles to modulate behavior. Additionally, 5-HT1B Rs are located throughout the brain and overlapping localization of hetero- and autoreceptors makes pharmacological manipulation an ineffective tool to isolate the two populations.

There is preclinical evidence that supports the role of 5-HT1B autoreceptors in the modulation of anxiety and depressive behaviors. Viral overexpression of 5-HT1BR in the raphe results in increased anxiety behavior following stressors (Clark et al, 2002), and 5-HT1B mRNA in the raphe is elevated in models of depression, such as learned helplessness, and following stress (Neumaier et al, 2001).
Additionally, reductions in 5-HT\textsubscript{1B} autoreceptors are associated with antidepressant treatment. Specifically, following SSRI treatment, 5-HT\textsubscript{1B}R mRNA is reduced in the raphe but not in the hippocampus, cortex, or striatum, suggesting that this effect is specific to autoreceptors (Anthony \textit{et al.}, 2000; Neumaier \textit{et al.}, 1996). Other studies also show desensitization of 5-HT\textsubscript{1B} autoreceptors following SSRI treatment (Davidson and Stamford, 2000). Furthermore, in humans a recent PET study showed that following successful cognitive behavioral therapy treatment for depression, 5-HT\textsubscript{1B}R binding is reduced in the brain stem region that contains the raphe (Tiger \textit{et al.}, 2014). Taken together, these data suggest a role for 5-HT\textsubscript{1B} autoreceptors in depression-related behaviors.

The current studies were designed to test if a reduction of 5-HT\textsubscript{1B} autoreceptors was sufficient to produce an antidepressant-like effect. To address this question, we used a genetic approach to selectively ablate 5-HT\textsubscript{1B}Rs from serotonin cells in mice, and measured the resulting effect on anxiety and depressive behaviors. We used a mouse in which a floxed tetracycline operator (tetO)-5-HT\textsubscript{1B} cDNA cassette was inserted in place of the endogenous coding region of htr1b to generate Htr1B\textsuperscript{floxed/tetO1B} mice (referred to as floxed teto1B) as previously described (Nautiyal \textit{et al.}, 2015). Crossing the floxed teto1B mouse to a transgenic mouse expressing Cre recombinase under the control of the Pet-1 promotor (Scott \textit{et al.}, 2005) allowed selective knockout of 5-HT\textsubscript{1B}R autoreceptors. Our results show that mice that lack 5-HT\textsubscript{1B} autoreceptors have increased levels of serotonin in the hippocampus in response to an SSRI, and show reduced depressive and anxiety-like behavior.

**MATERIALS AND METHODS**

**Animals**

Mice were bred in the Department of Comparative Medicine animal facility at the New York State Psychiatric Institute (NYSPI) at the Columbia University Medical Center. The floxed teto1B mouse model was used to generate groups of mice with alterations in 5-HT\textsubscript{1B}R expression (Nautiyal \textit{et al.}, 2015). Autoreceptor 5-HT\textsubscript{1B}R knockout was achieved by crossing teto1B mice to mice expressing Cre recombinase (Cre) or tetracycline-controlled transcriptional silencer (tTS) under the control of the Pet-1 promoter (Scott \textit{et al.}, 2005) allowing selective knockout of 5-HT\textsubscript{1B}R autoreceptors. Our results show that mice that lack 5-HT\textsubscript{1B} autoreceptors have increased levels of serotonin in the hippocampus in response to an SSRI, and show reduced depressive and anxiety-like behavior.

**Tissue Processing**

Brains were extracted from ePet-Cre+ or Pet-tTS+ mice and littermate controls and frozen immediately on crushed dry ice and maintained at −80 °C until sectioned using a cryostat (CM3050 S; Leica Biosystems, Wetzlar, Germany). Coronal brain sections, cut at 20 μm for adult tissue and 25 μm for PN7 tissue, were thaw-mounted on Superfrost slides (Fisher, Fair Lawn, NJ), and maintained at −80 °C until processing for receptor autoradiography or in situ hybridization.

 Autoradiography for 5-HT\textsubscript{1A} and 5-HT\textsubscript{1B} receptors and the serotonin transporter (SERT) was performed on every sixth section throughout the brain (Saudou \textit{et al.}, 1994). For 5-HT\textsubscript{1B} sections were incubated in 70 pM of \textsuperscript{125}I-cyanopindolol (10 μl/10 ml buffer; Perkin Elmer, Waltham, MA), 3 μM isoproterenol, 100 nM 8-OH-DPAT, 0.3% BSA, 0.01% ascorbic acid, and 10 μM pargyline (Sigma-Aldrich, St Louis, MO) for 2 h. For 5-HT\textsubscript{1A} sections were incubated in 4-(2′-methylpyrpylphenyl)-1-[2′-(n-2′′-pyridinyl)-p-\textsuperscript{125}I]iodobenzamido] ethylpiperazine ([\textsuperscript{125}I]-MPP) for 1 h. For SERT, sections were incubated in 50 pM of [\textsuperscript{125}I]-RTI155 with 100 μM nomifensine for 1 h, with nonspecific binding determined with 1 μM of fluoxetine. Slides were then elevated plus maze. Subsequently, these mice plus additional naïve mice (N = 17 ePet-Cre− and N = 17 ePet-Cre+) were run in the forced swim test 1 to 3 weeks later. Of these added mice, N = 8 ePet-Cre− and N = 8 ePet-Cre+ mice were randomly chosen and tested in a conditioned fear experiment 7 days following the forced swim test. A naïve cohort of N = 11 ePet-Cre− and N = 9 ePet-Cre+ mice was used for the sucrose preference experiment. N = 16 Pet-tTS− and N = 15 Pet-tTS+ mice were run in the open field test, then the forced swim test 7 days later (except for one Pet-tTS− mouse that was lost to attrition before being tested in the forced swim test). A separate group of mice was used for microdialysis studies (N = 8 ePet-Cre− and N = 9 ePet-Cre+). Additional groups of mice were also used for autoradiography and in situ hybridization characterization (N = 4/group).

Mice were group-housed 3–5 per cage following weaning at postnatal day (PN) 21, in plastic shoebox cages (Allentown Caging: 18 cm × 30 cm × 13 cm) with Bed-o’Cobs bedding (Anderssons, Maumee, OH) in ventilated racks. Food (Prolab Isopro RMH 3000, PMI Nutrition, St Louis, MO) and water were provided ad libitum except during sucrose preference experiments as described below. Animals were maintained on a 12 h : 12 h light–dark cycle and all behavioral testing was conducted during the light cycle. All animal care and testing was approved by the NYSPI Institutional Animal Use and Care Committee and was in accordance with the NIH’s Guide for the Care and Use of Laboratory Animals. All experiments, with the exception of microdialysis studies, were carried out in the Department of Comparative Medicine Facility at NYSPI. Microdialysis studies were performed at the Faculté de Pharmacie, Université Paris-Sud, Châtenay-Malabry, France, in compliance with the protocols approved by the Institutional Animal Care and Use Committee (Council directive # 87–848, 19 October 1987, Ministère de l’Agriculture et de la Forêt, Service Vétérinaire de la Santé et de la Protection Animale, permission # 92–196 to AMG).
In situ hybridization for 5-HT1B mRNA was performed based on the Allen Brain Atlas protocol using a digoxigenin (DIG)-labeled htr1b cRNA probe (Tanaka et al., 2012), as previously described (Nautiyal et al., 2015). Briefly, sections were fixed, washed, and treated with 0.2 M HCl and Proteinase K (40 μg/ml for adult tissue and 10 μg/ml for PN7 tissue; Roche, Basel, Switzerland) before a second fixation, acetylation, and prehybridization. Hybridization was carried out with a DIG-labeled htr1b probe (labeled using a probe-labeling kit; Roche) for 20 h at 65°C. The probe was visualized using anti-DIG phosphatase-conjugated antibody (at 1:5000 dilution; Roche) and nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate p-toluidine salt (NBT/BCIP) color substrate (Roche). Staining was visualized on a Zeiss AxioVert200 microscope (Oberkochen, Germany), and images were acquired using an attached Q-Imaging camera and associated QCapture Software (Surrey, Canada).

In Vivo Microdialysis

Mice were anesthetized (chloral hydrate 400 mg/kg i.p.) and implanted with concentric microdialysis probes made of cuprophan fibers (active length 2 mm, outer diameter 0.3 mm) located in the ventral hippocampus (stereotaxic coordinates AP: −2.8 mm, LL: ±3.0 mm, DV: −4.0 mm, according to Paxinos and Franklin (2001)). Animals were allowed to recover from the surgery overnight. The next day, the probes were continuously perfused with artificial cerebrospinal fluid (composition in mM: NaCl 147, KCl 3.5, CaCl2 1.26, MgCl2 1.2, NaHCO3 25, NaH2PO4 1.0, pH 7.4 ± 0.2) at a flow rate of 1.5 μl/min using a CMA/100 pump (Carnegie Medicin, Stockholm, Sweden) as previously described (Trillat et al., 1997). The animals were awake and freely moving in their cage during the microdialysis protocol. Samples were collected from the ventral hippocampus every 15 min, for 60 min before (to determine the basal values) and after an injection of escitalopram (5 mg/kg i.p.) (Nguyen et al., 2013), and for another 60 min following GR 127935, 2′-methyl-4′-(5-methyl-[1,2,4] oxadiazol-3-yl)-biphenyl-4-carboxylic acid, administration (5 mg/kg s.c.) (Gardier et al., 2003; Malage et al., 2001). Samples were analyzed for 5-HT levels using HPLC (column Ulimex 3 μm C18, 75 × 4.60 mm, particle size 3 μm; Phenomenex, Torrance, CA) coupled to an amperometric detector (VT03; Antec, Leyden, The Netherlands). Basal values were averaged and used as a baseline to calculate percent change following drug injections. Area under the curve (AUC) values for drug treatments were calculated using values from 30 to 60 min post injection.

For confirmation of probe placement, mice were cervically dislocated and the brains were quickly removed and frozen on dry ice and stored at −80°C until sectioning into 20 μm coronal slices mounted directly onto slides. Sections were fixed for 1 h in 4% PFA, incubated for 1 min in cresyl violet (0.3%), dehydrated in ethanol and overslipped with Permount (Thermo Fisher Scientific, Waltham, MA). Images of the sections were scanned (Epson perfection V500) and inserted in Adobe Illustrator, and probe localization was determined and mapped onto a brain atlas.

Behavioral Assays

For the open field assay, mice were placed individually into plexiglass enclosures 43 × 43 cm² in size with 30.5 cm high walls (Med Associates), and allowed to explore undisturbed for 30 min. Movements were recorded by beam breaks of two sets of 16 infrared photobeams. The center region was defined by the inner 21.2 cm × 21.2 cm area. Total distance, percent center distance (the percent of the total distance that occurs in the center region), time in center, and center entries were analyzed by MED Associates software. The arena was lit at ~ 400 lux.

In the elevated plus maze, mice were videotaped while allowed to explore undisturbed for 5 min. The maze had four arms (7.6 cm wide by 28 cm long) that were 31 cm above the floor. The two opposing closed arms had 15 cm high walls, while the two opposing open arms had a 1 cm lip. Behavior was scored using TopScan (CleverSys, Reston, VA) for number of entries and time spent in each arm.

To assess fear behavior, mice were tested in a one-trial contextual fear conditioning paradigm. Specifically, mice were allowed to freely explore the fear conditioning boxes (Coulbourn Instruments) for 180 s with the lights and fan on. Following 180 s, mice received a 1 s long 0.8 mA shock, and then remained in the box for an additional 20 s before they were removed to their home cage. The following day, mice were placed back into the same context for 180 s. On the third day, mice were placed into the boxes with a significantly different context for 180 s. This new context consisted of wood-shaving bedding (instead of metal bars), a lemon scent, with the lights off and a circular plastic enclosure obscuring the metal walls. Behavior was videotaped and the amount of time spent freezing was quantified using FreezeView software (Actimetrics, Wilmette, IL).

The forced swim test was conducted as previously described (Cryan et al., 2002) for 6 min on each of 2 days, with testing separated by 24–26 h. The test was conducted in a 31 transparent plastic beaker (22 cm height, 16.5 cm diameter) with a water depth of 15 cm and a water temperature of 26–27°C. Cage-mates were tested simultaneously (3–5 mice at a time) in individual beakers separated by an opaque shield. Mobility was analyzed throughout both sessions using ViewPoint Life Sciences Software.

Sucrose preference was measured using two bottle preference tests. Mice were water restricted and trained to consume daily liquids within 30 min by gradually decreasing fluid availability over 4 days. Following training, mice were placed separately in cages daily for 30 min with access to two bottles for measurement of consumption. Bottles initially
contained water; then increasing concentrations of sucrose (2, 4, 8, and 16%) were presented. Before a choice test was performed at any concentration of sucrose, it was first presented in both bottles for 2 days. Then, on the four subsequent days, mice were presented with one bottle of water and one bottle of sucrose, switching the side of the bottle every day. Sucrose preference was calculated for each day by dividing the sucrose intake over the total fluid intake, corrected for individual body weight, and then averaged over the 4 days.

Novelty-suppressed feeding was measured following 18 h of food deprivation. Mice were placed into a novel arena consisting of a plastic box (50 × 50 × 20 cm). The floor was covered with approximately 2 cm of wood shaving bedding and a single pellet of food was placed on a white paper platform in the center of the arena, secured to the platform with a rubber band. Mice were placed individually in a corner of the arena and the latency to eat (defined as the mouse sitting on its haunches and biting the pellet with the use of forepaws) was recorded, with a maximum allowed latency of 300 s.

Statistical Analysis

One-way analysis of variance (ANOVA) was used to assess the effect of genotype on behavior in the open field and elevated plus maze assays, and to test baseline differences for serotonin microdialysis. Repeated measures ANOVAs were used to examine the effect of genotype over brain regions for autoradiography, over days for forced swim and contextual fear tests, over time for microdialysis data, over sucrose concentrations for the sucrose preference test, and over SSRI treatment lengths for the novelty suppressed feeding test. Fisher’s PLSD was used for post hoc testing when significant main effects were observed. StatView software was used for all analyses, and effects were considered statistically significant when p-values were less than 0.05.

RESULTS

Floxed tetO1B mice were generated to enable tissue-specific knockdown of 5-HT1BRs (Nautiyal et al., 2015). In the absence of Cre or tTS, mice have normal levels of 5-HT1BR as previously reported (Nautiyal et al., 2015). Crossing floxed tetO1B mice to a line expressing Cre under the Pet-1 promotor (Scott et al., 2005) allowed for 5-HT1B autoreceptor knockout (Figure 1a). There was reduced 5-HT1B mRNA in the raphe of floxed tetO1B::ePet-Cre+ (referred to as ePet-Cre+) mice compared with floxed tetO1B::ePet-Cre− (ePet-Cre−) littermate controls (Figure 1b). Quantification revealed significantly fewer 5-HT1B mRNA+ cells in the raphe of ePet-Cre+ mice (F1,6 = 44.3, p < 0.01), but no significant effect in the periaqueductal gray, a nearby brain region that also expresses 5-HT1BR mRNA (Figure 1c; F1,6 = 1.9, p > 0.05). In contrast, receptor autoradiography for 5-HT1B protein localization revealed no detectable differences in 5-HT1B levels between ePet-Cre+ and control mice across all brain regions (Figure 1d and e; F1,6 = 0.9, p > 0.05), consistent with previous reports showing small, if any,
changes in receptor binding following lesions of serotonin cells (Compan et al., 1998; Offord et al., 1988; Pranzatelli et al., 1996). Additionally, to assess compensatory effects of 5-HT1B autoreceptor knockout, receptor autoradiography for 5-HT1AR and SERT was also performed (Supplementary Figure S1A and C). There were no significant differences between ePet-Cre+ and ePet-Cre− mice in 5-HT1AR binding throughout the brain (Supplementary Figure S1B; F1,8 = 0.56, p > 0.05). There was a small, but significant increase in SERT binding in the ventral hippocampus of ePet-Cre+ mice (Supplementary Figure S1D; F1,6 = 8.8, p < 0.05), consistent with the increase reported in the constitutive 5-HT1B KO mice (Ase et al., 2001).

We next measured the functional effect of 5-HT1B autoreceptor knockout on extracellular serotonin levels in the ventral hippocampus using microdialysis (Figure 2). There were significant effects of 5-HT1B autoreceptor knockout on 5-HT levels following SSRI treatment (Figure 2a and b; F3,30 = 6.5, p < 0.01). Specifically, following peripheral injection of escitalopram, ePet-Cre+ mice had significantly higher levels of serotonin in the ventral hippocampus compared with ePet-Cre− littermate controls beginning 30 min post injection (F1,15 = 5.0, p < 0.05). Following a subsequent injection of GR 127935, a 5-HT1BR antagonist, ePet-Cre− mice showed elevations in 5-HT to levels seen in ePet-Cre+ mice by 30 min post injection (F1,15 = 0.5, p > 0.05). There was no effect of GR 127935 injection on 5-HT levels in ePet-Cre+ mice (F1,14 = 0.1, p > 0.05). There were also no detectable baseline differences between genotypes (F1,15 = 0.1, p > 0.05), as seen previously in male mice (Jones and Lucki, 2005). These data point to a functional role for 5-HT1B autoreceptor in the regulation of hippocampal 5-HT levels.

Next, we assessed the effects of 5-HT1B autoreceptor knockout on anxiety and depression-related behavior. An absence of 5-HT1B autoreceptors in ePet-Cre+ mice resulted in decreased anxiety-like behavior. Specifically, in the open field test, ePet-Cre+ mice spent more time in the center of the arena compared to littermate ePet-Cre− mice (Figure 3a; F1,23 = 8.8, p < 0.01). They were also more active overall as measured by distance travelled (Figure 3b; F1,23 = 5.8, p < 0.05). Additionally, after controlling for the increased distance overall, ePet-Cre+ mice had an increased activity in the center of the arena compared with ePet-Cre− control mice (% center distance; Figure 3c; F1,23 = 5.1, p < 0.05). There was also a trend towards increased number of entries into the center compared with littermate control ePet-Cre+ mice (F1,23 = 4.2, p = 0.05). Consistent with the open field data, there was also a trend towards decreased anxiety-like behavior in ePet-Cre+ mice in the elevated plus maze, namely a trend towards more entries into the open arms in ePet-Cre+ mice compared with ePet-Cre− controls (Supplementary Figure S2A; F1,26 = 3.0, p = 0.095). There were no significant effects on the time spent in the open arms or in the total number of entries into all arms (Supplementary Figure S2B and C; F1,26 < 1.7, p > 0.05). Finally, given past evidence suggesting a role for 5-HT1B autoreceptors in modulating learned fear behavior, we tested the response of ePet-Cre+ mice in a one trial contextual fear conditioning paradigm (Supplementary Figure S2D). While all mice showed increased freezing to the context following shock (F2,28 = 41.3, p < 0.001), we found no significant effects of genotype on freezing, suggesting no effect of life-long knockout of 5-HT1B autoreceptors on context-based learned fear responses (F1,14 = 0.1, p > 0.05).

We also assessed the effects of the absence of 5-HT1B autoreceptors on depressive-like behavior and found significant antidepressant-like effects in the ePet-Cre+ mice. In the forced swim test, they displayed increased mobility compared with littermate Cre− controls (Figure 4a; F1,56 = 6.02, p < 0.05). Specifically, this effect was seen on day 2 with ePet-Cre+ mice (p < 0.01), mimicking an
antidepressant-like response. Mice were also assessed in the sucrose preference test as a test of anhedonia or depression-related behavior, which is independent of activity levels. ePet-Cre+ mice showed increased preference for lower concentrations of sucrose compared with ePet-Cre− mice (Figure 4b; $F_{1,18} = 11.8$, $p < 0.01$). ePet-Cre+ mice preferred 2 and 4% sucrose significantly more than Cre− controls ($p < 0.05$). There was also a trend for increased preference at 8% in ePet-Cre+ mice ($p = 0.05$), with a significant increase in total consumption of the 8% sucrose solution ($p < 0.05$). There was no significant difference in body weights between the groups (25.5 ± 1.1 g for ePet-Cre− and 24.7 ± 0.4 g for ePet-Cre+; $F_{1,18} = 1.3$, $p > 0.05$). There was also no effect on the amount of fluid consumption corrected for body weight (0.081 ± 0.004 and 0.084 ± 0.003 ml/g of body weight for ePet-Cre− and ePet-Cre+ mice, respectively; $F_{1,18} = 0.2$, $p > 0.05$), suggesting that the effect was not a result of change in thirst.

Given the increased levels of extracellular 5-HT following SSRI administration, we assessed the behavioral response to SSRI treatment (Supplementary Figure S3). Fluoxetine reduced the latency to eat in the novel arena ($F_{2,28} = 5.1$, $p < 0.05$), regardless of genotype ($F_{1,14} = 0.01$, $p > 0.05$). More specifically, chronic (21 days), but not subchronic (10 days), treatment reduced the latency to eat from the pre-treatment baseline in both ePet-Cre− and ePet-Cre+ mice. The lack of any increased efficacy of SSRI treatment seen in ePet-Cre+ mice may have been due to limited group sizes, the remaining presence of 5-HT1A autoreceptors, or differential circuitry underlying baseline depressive-like behavior compared with antidepressant responses.

Lastly, we addressed the potential developmental effect of 5-HT1B autoreceptor knockdown by crossing floxed tetO1B mice to the Pet-tTS line. Floxed tetO1B::Pet-tTS+ (referred to as Pet-tTS+) mice lack autoreceptors during development, but not adulthood (Figure 5a). Pet-tTS+ mice showed
normal levels of 5-HT\textsubscript{1B} mRNA in the raphe compared with littermate Pet-tTS\textsuperscript{−} controls (Figure 5b, \(F_{1,6} = 1.3, p > 0.05\)). However, at postnatal day (PN) 7, mRNA in the raphe of Pet-tTS\textsuperscript{+} mice was significantly reduced compared with littermate Pet-tTS\textsuperscript{−} controls (Figure 5c; \(F_{1,6} = 7.1, p < 0.05\)). There were no significant effects of genotype on the number of 5-HT\textsubscript{1B} mRNA\textsuperscript{+} cells in the rostromedial tegmental area (RMTg) of either adult or PN7 mice (F\textsubscript{1,6} = 0.4, p > 0.05 for adults; F\textsubscript{1,4} = 0.3, p > 0.05 for PN7). Behaviorally, there were no significant differences between Pet-tTS\textsuperscript{+} mice and controls in the forced swim test or open field arena, two tests in which Pet-Cre\textsuperscript{+} mice differed significantly from controls. In the forced swim test, Pet-tTS mice showed no differences in time immobile compared with littermate controls (Figure 5d; \(F_{1,28} = 0.03, p > 0.05\)). There were also no significant effects of developmental 5-HT\textsubscript{1B} autoreceptor knockdown in the open field tests of total distance (Figure 5e; \(F_{1,29} = 1.06, p > 0.05\)), time in center (Figure 5f; \(F_{1,29} = 1.66, p > 0.05\)), or % center distance (Figure 5g; \(F_{1,29} = 3.35, p = 0.08\)). In fact, there was a trend for increased anxiety-like behavior in the open field (center time and center distance), which is the opposite of what was found with the whole-life knockout of the autoreceptor. The lack of effects on behavioral tests in the developmental 5-HT\textsubscript{1B} autoreceptor knockdown suggests that 5-HT\textsubscript{1B} autoreceptors are involved in modulating anxiety and depression-like behavior primarily during adulthood.

DISCUSSION

The results presented show that an absence of 5-HT\textsubscript{1B} autoreceptors throughout life results in an antidepressant-like phenotype—including decreased anxiety-like behavior in the open field and decreased depressive-like behavior in the forced swim and sucrose preference tests. Furthermore, we found increased extracellular serotonin levels in the ventral hippocampus of ePet-Cre\textsuperscript{+} mice in response to SSRI administration, suggesting a functional role for 5-HT\textsubscript{1B} autoreceptors in the regulation of serotonin release in the hippocampus. These increases in serotonin levels and antidepressant-like phenotypes have been seen previously in the ubiquitous 5-HT\textsubscript{1B}R KO (Bechtholt \textit{et al}, 2008; Jones and Lucki, 2005; Knobelman \textit{et al}, 2001; Mayorga \textit{et al}, 2001), but importantly, our genetic model allowed the dissociation of the role of 5-HT\textsubscript{1B} autoreceptors from heteroreceptors. This advancement is significant since pharmacological dissection via local infusion of antagonists or agonists is not possible given the terminal localization of 5-HT\textsubscript{1B} autoreceptors throughout the brain (McDevitt and Neumaier, 2011). The identification of a population of 5-HT\textsubscript{1B} receptors involved in modulating anxiety and depression is important given the diverse physiological effects which 5-HT\textsubscript{1B}Rs can cause depending on their localization. In fact, there is evidence which suggests an opposing role of 5-HT\textsubscript{1B} heteroreceptors on anxiety and depressive behaviors. Namely, activation of 5-HT\textsubscript{1B}...
heteroreceptors in a serotonin depletion model (to remove the contribution of autoreceptors) results in an antidepressant-like effect (Chenu et al, 2008). Additionally, reduced expression of 5-HT1B heteroreceptors in the ventral striatum is associated with depression in humans (Murrough et al, 2011b). Finally, these ventral striatal 5-HT1B heteroreceptors have been suggested to interact with p11 (a 5-HT1BR-binding protein) to affect depression-related behavior (Alexander et al, 2010; Svenningsson et al, 2006).

The increased extracellular serotonin levels in the hippocampus of ePet-Cre+ mice provide a possible mechanism of the behavioral effects seen between ePet-Cre− and ePet-Cre+ mice. Although we did not observe baseline differences in extracellular serotonin levels, consistent with previous reports in male mice (Jones and Lucki, 2005; Trillat et al, 1997), there may be differences between genotypes during specific behavioral tests resulting in higher serotonergic tone in the brains of Cre+ mice. In fact, increases in serotonin release have been seen in the brains of mice following 5-HT1A autoreceptor knockdown with siRNA during tests of depressive behaviors, despite an absence in baseline differences (Ferres-Coy et al, 2013). Another potential mechanism through which 5-HT1B autoreceptors could modulate anxiety and depression-like behavior is via effects on SERT function, given the impact of 5-HT1B autoreceptors on the regulation of SERT activity and expression (Hagan et al, 2012; Montanez et al, 2014). While there were increases in levels of 5-HT in the hippocampus in ePet-Cre+ mice following inhibition of SERT function with SSRIs, preliminary studies showed no differential effect of SSRIs on behavior (Supplementary Figure S3). Lastly, another possibility includes a developmental contribution of 5-HT1B autoreceptors to the maturation of neural circuits underlying these behaviors. However, our data showing a lack of significant effects of developmental knockdown in forced swim or open field behavioral tests (see Figure 5) suggest that the effect of 5-HT1B autoreceptors on anxiety and depressive-like behavior is likely not mediated during early postnatal development.

Overall, our data are consistent with evidence suggesting a pre-depressive role for the activation of 5-HT1B autoreceptors (Neumaier et al, 1997, 2002). However, there are also seemingly contradictory results. Specifically, studies report that increasing 5-HT1B autoreceptor levels in the dorsal raphe using viral-mediated overexpression results in anxiolytic, antidepressive, and reduced fear behavior in rats (Clark et al, 2004; McDevitt et al, 2011). One difference between these results and our studies may be a result of cell-type specificity since the viral overexpression was not limited to serotonin cells. Specifically, GABAergic neurons in the raphe may express 5-HT1B and overexpression in these cells may oppose the actions of 5-HT1B autoreceptors (Weissbourd et al, 2014). In fact, the presence of remaining 5-HT1B mRNA-containing cells in the raphe of ePet-Cre+ mice (see Figure 1) may correspond to these non-serotonin cells that express 5-HT1B. Another intricacy that has been previously suggested is that the role of 5-HT1B autoreceptors may not be homogeneous throughout the raphe, but rather, receptors with different rostral-caudal localization within the dorsal raphe may have distinct effects (Clark et al, 2006; McDevitt et al, 2011). These location-specific manipulations are different from the genetic manipulation used here that results in knockout of 5-HT1BR throughout the dorsal and median raphe.

Interestingly, the role of 5-HT1B autoreceptors seems divergent from that of the well-studied 5-HT1A autoreceptors (Garcia-Garcia et al, 2014). Our data suggest a substantially different role for the 5-HT1A and 5-HT1B autoreceptors in the modulation of anxiety and depression-like behavior. For example, whole-life knockout of 5-HT1A autoreceptors results in increased anxiety and no change in depression-like behavior (Richardson-Jones et al, 2011), which contrasts with the decreased anxiety and depressive-like behavior that we report here with whole life knockout of 5-HT1B autoreceptors. The anxiety phenotype in the 5-HT1A autoreceptor knockout is likely due to the absence of the receptor during postnatal development (Donaldson et al, 2014), which is possibly related to the trend we observe in the developmental knockout of the 5-HT1B autoreceptors. Interestingly, adult knockout of 5-HT1A autoreceptors results in decreased depressive-like behaviors (Richardson-Jones et al, 2010), which is analogous to our findings in whole-life knockout of 5-HT1B autoreceptors. These results are consistent with the fact that this antidepressant-like phenotype likely results from the absence of the 5-HT1B autoreceptor during adulthood (since it is not observed in the developmental knockout). The disparities in effects of the 5-HT1A and 5-HT1B autoreceptors may be due to the differential subcellular localization, as 5-HT1A is somatodendritic and 5-HT1B is located at the presynaptic terminal (Ghavami et al, 1999). This differential localization may point to their roles in different circuits which contribute to depressive behavior (Knobelmann et al, 2001). While the expression of 5-HT1A and 5-HT1B is overlapping in the raphe, small differences in the regional localization of the receptors within the raphe may also contribute to differences in receptor function (Clark et al, 2006). Finally, another possibility is that the 5-HT1A and 5-HT1B receptors may engage different non-canonical intracellular signaling cascades that lead to the different behavioral effects (Albert and Tiberi, 2001; Polter and Li, 2010).

While the mechanisms underlying the effects of these serotonin autoreceptors on anxiety and depressive behavior are unknown, these studies highlight the complexity of serotonergic modulation of affective behavior. Additional studies are needed to address the mechanisms of the effects of 5-HT1B autoreceptors on depressive-like behaviors as well as interactions of sex with these effects (Jones and Lucki, 2005). Given the various underlying serotonergic mechanisms, it is interesting that a lack of 5-HT1B autoreceptors was sufficient to generate antidepressant and anxiolytic responses. Taken together with studies showing dysregulation of 5-HT1BRs in mood disorders in humans (Murrough et al, 2011a,b) and the potential involvement of 5-HT1BRs in antidepressant responses (Tiger et al, 2014; Yamanaka et al, 2014), our results suggest the potential benefit of strategies aimed at targeting 5-HT1B autoreceptor signaling for the treatment of anxiety and depression.

FUNDING AND DISCLOSURE
Funding was provided by NIH F32 MH100888 (to KMN), NIH K99 MH106731 (to KMN), Early Stage Investigator
Award from the National Center for Responsible Gaming (to KMN), Sackler Institute Award (to KMN), NIH K08MH087718 (to SEA), Hope for Depression Research Foundation (to RH), NIH R01 MH083862 (to RH), and NIH R37 MH068542 (to RH). RH receives compensation as a consultant from Lundbeck and Roche. DJD currently receives investigator-initiated research support from Lundbeck and served as a consultant in the areas of target identification and validation and new compound development to Lundbeck Inc., Roche, and Servier. The authors declare no potential conflict of interest.

ACKNOWLEDGMENTS
We thank Valerie Magalong, Salomon Muller, Jennifer Payne, and Anna Poszmiłk for technical assistance.

REFERENCES
Knobelman DA, Hen R, Lucki I (2001). Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse. J Pharmacol Exp Ther 298: 1083–1091.


Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)